182 related articles for article (PubMed ID: 38862980)
1. Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues.
Kumar KK; Aburawi EH; Ljubisavljevic M; Leow MKS; Feng X; Ansari SA; Emerald BS
Clin Epigenetics; 2024 Jun; 16(1):78. PubMed ID: 38862980
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors as antidiabetic agents: Advances and opportunities.
Sonthalia M; Roy BS; Chandrawanshi D; Ganesh GV; Jayasuriya R; Mohandas S; Rajagopal S; Ramkumar KM
Eur J Pharmacol; 2022 Nov; 935():175328. PubMed ID: 36257383
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes.
Sharma S; Taliyan R
Pharmacol Res; 2016 Nov; 113(Pt A):320-326. PubMed ID: 27620069
[TBL] [Abstract][Full Text] [Related]
4. The Emerging Role of HDACs: Pathology and Therapeutic Targets in Diabetes Mellitus.
Dewanjee S; Vallamkondu J; Kalra RS; Chakraborty P; Gangopadhyay M; Sahu R; Medala V; John A; Reddy PH; De Feo V; Kandimalla R
Cells; 2021 May; 10(6):. PubMed ID: 34071497
[TBL] [Abstract][Full Text] [Related]
5. Phenylbutyrate and β-cell function: contribution of histone deacetylases and ER stress inhibition.
Khan S; Komarya SK; Jena G
Epigenomics; 2017 May; 9(5):711-720. PubMed ID: 28470097
[TBL] [Abstract][Full Text] [Related]
6. MC1568 improves insulin secretion in islets from type 2 diabetes patients and rescues β-cell dysfunction caused by Hdac7 upregulation.
Daneshpajooh M; Eliasson L; Bacos K; Ling C
Acta Diabetol; 2018 Dec; 55(12):1231-1235. PubMed ID: 30088095
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children.
Lundh M; Christensen DP; Damgaard Nielsen M; Richardson SJ; Dahllöf MS; Skovgaard T; Berthelsen J; Dinarello CA; Stevenazzi A; Mascagni P; Grunnet LG; Morgan NG; Mandrup-Poulsen T
Diabetologia; 2012 Sep; 55(9):2421-31. PubMed ID: 22772764
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of histone deacetylase 3 (
Sathishkumar C; Prabu P; Balakumar M; Lenin R; Prabhu D; Anjana RM; Mohan V; Balasubramanyam M
Clin Epigenetics; 2016; 8():125. PubMed ID: 27904654
[TBL] [Abstract][Full Text] [Related]
9. HDAC7 is overexpressed in human diabetic islets and impairs insulin secretion in rat islets and clonal beta cells.
Daneshpajooh M; Bacos K; Bysani M; Bagge A; Ottosson Laakso E; Vikman P; Eliasson L; Mulder H; Ling C
Diabetologia; 2017 Jan; 60(1):116-125. PubMed ID: 27796421
[TBL] [Abstract][Full Text] [Related]
10. Valproic Acid Improves Glucose Homeostasis by Increasing Beta-Cell Proliferation, Function, and Reducing its Apoptosis through HDAC Inhibition in Juvenile Diabetic Rat.
Khan S; Jena G
J Biochem Mol Toxicol; 2016 Sep; 30(9):438-46. PubMed ID: 27079868
[TBL] [Abstract][Full Text] [Related]
11. Isoform-selective inhibitor of histone deacetylase 3 (HDAC3) limits pancreatic islet infiltration and protects female nonobese diabetic mice from diabetes.
Dirice E; Ng RWS; Martinez R; Hu J; Wagner FF; Holson EB; Wagner BK; Kulkarni RN
J Biol Chem; 2017 Oct; 292(43):17598-17608. PubMed ID: 28860191
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.
Christensen DP; Dahllöf M; Lundh M; Rasmussen DN; Nielsen MD; Billestrup N; Grunnet LG; Mandrup-Poulsen T
Mol Med; 2011; 17(5-6):378-90. PubMed ID: 21274504
[TBL] [Abstract][Full Text] [Related]
13. Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents.
Wahi A; Jain P; Sinhari A; Jadhav HR
Naunyn Schmiedebergs Arch Pharmacol; 2024 Feb; 397(2):675-702. PubMed ID: 37615708
[TBL] [Abstract][Full Text] [Related]
14. Class IIa HDACs do not influence beta-cell function under normal or high glucose conditions.
McCann J; Ellis M; McGee SL; Aston-Mourney K
Islets; 2019; 11(5):112-118. PubMed ID: 31112063
[TBL] [Abstract][Full Text] [Related]
15. Role of HDAC inhibitors in diabetes mellitus.
Makkar R; Behl T; Arora S
Curr Res Transl Med; 2020 Apr; 68(2):45-50. PubMed ID: 31477543
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats.
Lundh M; Galbo T; Poulsen SS; Mandrup-Poulsen T
Diabetes Obes Metab; 2015 Jul; 17(7):703-7. PubMed ID: 25846481
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics.
Meier BC; Wagner BK
Epigenomics; 2014 Apr; 6(2):209-14. PubMed ID: 24811789
[TBL] [Abstract][Full Text] [Related]
18. Cellular Senescence in Diabetes Mellitus: Distinct Senotherapeutic Strategies for Adipose Tissue and Pancreatic β Cells.
Murakami T; Inagaki N; Kondoh H
Front Endocrinol (Lausanne); 2022; 13():869414. PubMed ID: 35432205
[TBL] [Abstract][Full Text] [Related]
19. HDACs as an emerging target in endocrine tumors: a comprehensive review.
Klieser E; Neumayer B; Di Fazio P; Mayr C; Neureiter D; Kiesslich T
Expert Rev Endocrinol Metab; 2023 Mar; 18(2):143-154. PubMed ID: 36872882
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase regulates insulin signaling via two pathways in pancreatic β cells.
Kawada Y; Asahara SI; Sugiura Y; Sato A; Furubayashi A; Kawamura M; Bartolome A; Terashi-Suzuki E; Takai T; Kanno A; Koyanagi-Kimura M; Matsuda T; Hashimoto N; Kido Y
PLoS One; 2017; 12(9):e0184435. PubMed ID: 28886131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
